Jazz Pharmaceuticals PLC.
JAZZ
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
PRNewsWire • 1 day ago • JAZZ
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
FXEmpire • 7 days ago • JAZZ
Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential
Seeking Alpha • 7 days ago • JAZZ
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Zacks Investment Research • 10 days ago • JAZZ
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
Seeking Alpha • 16 days ago • JAZZ
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.